Bionano Genomics
Bioinformatics, Biotechnology, Genetics · 50 employees
At Bionano, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home.
Funding history
- Funding Round — $20.0M — Jul 2024
- Funding Round — $20.0M — Jun 2024
- Funding Round — $35.0M — Oct 2023
- Funding Round — $41.9M — Oct 2021
- Series seed — $2.5M — Mar 2019
Recent signals
- Jan 12, 2026: SEC 8-K (2.02): On January 12, 2026, Bionano Genomics, Inc. reported its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. The company highlighted significant growth metrics, although specific financial amounts were not disclosed in the excerpt. This early indication of performance is expected to inform investors and stakeholders about the company's fiscal health and strategic direction. The press release is attached as Exhibit 99.1 to the Form 8-K, underlining its significance for compliance with financial reporting obligations.
- Oct 31, 2024: Bionano Genomics, Inc. Closes $3 Million Registered Direct Offering under Nasdaq Rules
- Jul 10, 2024: Raised $20.0M
- Jun 05, 2024: Raised $20.0M
- Oct 27, 2023: Raised $35.0M
- Nov 28, 2022: Acquired Bionano Genomics To Acquire Purigen Biosystems To Enable Further Simplified And Accelerated Dna Isolation For Optical Genome Mapping (Ogm) And Address Difficult Sample Types In New Applications With Isotachophoresis (Itp) On The Ionic Purification System
- Oct 25, 2021: Raised $41.9M
- Mar 28, 2019: Raised $2.5M in Series seed
See plans & pricing → Track Bionano Genomics’s funding, hiring, and signals — with verified contacts — on Fundz.